Related Experiment Video
Updated: Jun 24, 2026

Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
Luteolin Inhibits NLRP3 Inflammasome Activation to Ameliorate DSS-Induced Colitis by Regulating AMPK Signalling
Lianxiang Luo1, Fangfang Huang2, Guixuan Fang2
1School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang, Guangdong, China.
Luteolin, a natural compound, effectively treats ulcerative colitis in mice by inhibiting the NLRP3 inflammasome. This anti-inflammatory action involves reducing cellular stress and improving lipid metabolism, highlighting its therapeutic potential for inflammatory bowel disease.
Area of Science:
- Immunology
- Pharmacology
- Gastroenterology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease with limited treatment options.
- The NLRP3 inflammasome plays a critical role in UC pathogenesis by driving excessive inflammation.
- Targeting the NLRP3 inflammasome presents a potential therapeutic strategy for UC.
More Related Videos
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Crohn's Disease